LOGIN
ID
PW
MemberShip
2025-09-09 23:08
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Opinion
[Reporter's View] The revision of the Commercial Act
by
Kim, Jin-Gu
Jul 9, 2025 06:08am
The bill on revising the Commercial Act has passed the National Assembly. The bill expands the fiduciary duty of directors to include not only the ¡°company¡± but also ¡°shareholders,¡± mandates the introduction of electronic shareholder meetings for listed companies with assets of KRW 2 trillion or more, and changes the title of ¡°outside d
Opinion
[Reporter¡¯s View] NHI finances and reimb expansions
by
Lee, Jeong-Hwan
Jul 4, 2025 06:06am
Striking a balance between improving the financial sustainability of the national health insurance system and enhancing patient access to drugs for rare and intractable diseases is a national issue. The two issues that repeatedly come into conflict have long occupied the attention of all political parties in their search for solutions, ye
Opinion
[Reporter¡¯s View] Doctors agree Korea¡¯s reimb is too slow
by
Eo, Yun-Ho
Jul 2, 2025 06:09am
Even prescribing physicians believe that the pace of new drug reimbursement listing in Korea is too slow. This is an issue not only for doctors or patients, but obviously for pharmaceutical companies as well. Recently, the Korean Research-based Pharmaceutical Industry Association (KRPIA) released the results of a survey of 100 medical pro
Opinion
[Reporter's View] Divisional restructuring needed
by
Lee, Hye-Kyung
Jun 30, 2025 06:06am
During his candidacy, President Lee Jae-myung pledged to designate the biotech industry as a cutting-edge sector and build it as the future growth engine, aiming to position South Korea as one of the world's five strongest biotech countries. Based on an analysis that the previous government was short on investment in the pharmaceutical and bi
Opinion
[Reporter's View] For local gov't seeking biotech diplomacy
by
Whang, byung-woo
Jun 30, 2025 06:05am
'BIO USA,' held in Boston, U.S., is the world's largest biotech industry conference. Notably, this year's conference was attended by officials from Korea's local government. The attending officials aimed to promote local biotech clusters and seek potential investment partners. Through this event, they intended to establish a gamer-changer
Opinion
[Reporter's View] Silent efforts pay off in the market
by
Son, Hyung Min
Jun 25, 2025 06:02am
In the first half of this year, South Korean pharmaceutical and biotech companies achieved notable success through technology exports. A series of major licensing deals were signed based on the companies¡¯ innovative drug development platforms and clinical trial results the companies steadily developed and accumulated over the years. In A
Opinion
[Reporter's View] Telemedicine in a 5-sided tug-of-war
by
Lee, Jeong-Hwan
Jun 19, 2025 06:02am
With the election and inauguration of President Lee Jae-Myung, the Democratic Party of Korea, which successfully changed the administration, submitted a bill to revise the Medical Service Act that narrows the scope of telemedicine¡¯s initial consultation in the current pilot program to the National Assembly. As a result, the eyes of the
Opinion
[Desk View] Disclosing drug reimb info must be done properly
by
Lee, Tak-Sun
Jun 18, 2025 06:00am
Due to concerns about the non-transparency of the selection process for medicinal product reimbursement, the Health Insurance Review & Assessment Service (HIRA) and the National Health Insurance Service (NHIS) are disclosing partial processes and candidates. HIRA discloses, through press releases, the review results from the Cancer Drug Re
Opinion
[Reporter¡¯s View] Expectations for the second pilot project
by
Eo, Yun-Ho
Jun 17, 2025 05:59am
Several drugs that were undergoing concurrent regulatory approval and reimbursement evaluations for improved patient access are now approaching commercialization. However, whether these drugs will actually receive reimbursement coverage remains uncertain despite expedited approval timelines. Since 2023, the Ministry of Health and Welfare
Opinion
[Reporter's View] GMP standards for sterile products
by
Lee, Hye-Kyung
Jun 17, 2025 05:58am
The Ministry of Food and Drug Safety (MFDS) is devising measures to reduce the burden on the pharmaceutical industry ahead of the implementation of the 'Revised PIC/S Good Manufacturing Practices (GMP) Guide for Sterile Medicinal Products (guidelines on manufacturing and quality control of medicines)' in December. Following the administrative
1
2
3
4
5
6
7
8
9
10
>